Experienced in Cytochrome C Oxidase Deficiency

Maina P. Kava

15 Hospital Avenue, 
Nedlands, WA, AU 
Experienced in Cytochrome C Oxidase Deficiency
15 Hospital Avenue, 
Nedlands, WA, AU 
OverviewLocationsClinical Research

Overview

Maina Kava practices in Nedlands, Australia. Ms. Kava is rated as an Experienced expert by MediFind in the treatment of Cytochrome C Oxidase Deficiency. Her top areas of expertise are Glycine Encephalopathy, Pyridoxine Deficiency, Cytochrome C Oxidase Deficiency, and Becker Muscular Dystrophy.

Her clinical research consists of co-authoring 26 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Cytochrome C Oxidase Deficiency.

Gender
Female

Locations

15 Hospital Avenue, Nedlands, WA 6009, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Terminated
Publish Date: August 26, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension
A Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension
Enrollment Status: Completed
Publish Date: January 18, 2024
Intervention Type: Drug
Study Drug: Ataluren
Study Phase: Phase 3
View 1 Less Clinical Trial

26 Total Publications

A new tool for laryngeal electromyography in the Australian paediatric population.
A new tool for laryngeal electromyography in the Australian paediatric population.
Journal: International journal of pediatric otorhinolaryngology
Published: May 06, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Kava's expertise for a condition
ConditionClose
      View All 14 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile